The Anturane Reinfarction Trial: Reevaluation of Outcome

Publisher Website
Google Scholar
Abstract
The Anturane Reinfarction Trial, reported previously in the Journal, 1 , 2 was a randomized double-blind multicenter trial comparing the effects of sulfinpyrazone and a placebo on cardiac mortality after myocardial infarction. In this study, 1558 eligible patients were followed for an average of 16 months, beginning 25 to 35 days after infarction. A reduction in overall cardiac mortality was observed (P = 0.058), but this benefit occurred entirely during the first six months of treatment and appeared to be attributable to a decrease in the incidence of sudden death.Subsequently, a critique of this study by the FDA was published, also in . . .